Why Cancer Immunotherapy Fails Some Patients: The Key May Be Inside the Tumor, Not the Blood

A groundbreaking study by a Japanese research team suggests that the key to effective cancer immunotherapy might lie within the tumor itself, rather than in the patient's bloodstream. The research focuses on a protein called complement C3, which plays a role in the immune system's response to infections.

Published in Nature Communications, the study, led by researchers at Nagoya University, found that while C3 is typically produced by the liver and circulates in the blood, its presence within tumors could significantly alter its function. Experiments on mice showed that drastically reducing blood C3 levels (by 90%) had little impact on immunotherapy outcomes. However, when the production of C3 in the microenvironment surrounding tumors was inhibited, immunotherapy effectiveness decreased, even with only a minor reduction (about 9%) in blood C3.

This suggests that C3 generated within the tumor microenvironment acts differently. The researchers discovered that tumor-derived C3 can prevent the accumulation of cells that suppress immune responses within the tumor. By blocking these immunosuppressive cells, C3 appears to create a more favorable environment for immune cells to attack cancer, effectively clearing space for the immune system's assault on cancer cells.

Further experiments involved testing a drug that mimics C3's function. This approach restored treatment effectiveness in mouse tumors that had previously been unresponsive to immunotherapy, extending survival times. Analysis of lung cancer patient tumor samples also indicated a correlation: patients with higher C3 levels around their tumors showed better treatment responses and survival rates compared to those with lower C3 levels. Blood C3 concentration, conversely, showed no clear link to treatment outcomes.

The research team plans to investigate methods for increasing C3 levels within tumors and determining the optimal timing for such interventions. However, they emphasize that current results stem mainly from animal studies and patient sample analyses, and should not yet be considered a definitive human treatment method.